Stay updated on Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision: v3.4.2 is now displayed; the earlier government funding/operating status notice (Revision: v3.4.1) has been removed. This is an administrative update and does not affect the study details.SummaryDifference0.4%

- Check20 days agoChange DetectedAdded a site-wide notice about potential delays due to government funding and the NIH Clinical Center status. Updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check28 days agoChange DetectedThe additions and deletions are minor metadata and UI updates, including showing the glossary, new 'Last Update' fields, and a revision bump from v3.3.4 to v3.4.0, with some metadata items removed or reformatted. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check35 days agoChange DetectedAdded Principal Investigator: Timothy Voorhees, MD, and protocol implementation contact details (CTO.Implementation@osumc.edu; 614-293-3717) for Ohio State University Comprehensive Cancer Center. Expanded the Locations/Recruiting sections to six sites with explicit Columbus, Ohio addresses and updated recruitment status.SummaryDifference1%

- Check42 days agoChange DetectedRevision: v3.3.4 updates the page from v3.3.3; no study content or eligibility details appear affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedThe page now includes a dedicated Locations section listing study sites in Illinois, Indiana, Iowa, Minnesota, and Wisconsin. The separate Illinois Locations entry and related footer label have been removed as part of this update.SummaryDifference0.6%

Stay in the know with updates to Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial page.